AI Article Synopsis
- - Oral squamous cell carcinoma (OSCC) develops from precancerous lesions, influenced by oncogene activation and tumor suppressor gene loss, with Her2/neu being a significant growth factor receptor related to these changes.
- - A study compared serum and salivary Her2/neu levels among healthy controls, patients with premalignant disorders, and those with OSCC, finding no significant differences in serum but higher salivary levels in OSCC patients.
- - The findings suggest that salivary Her2/neu could serve as a reliable marker for distinguishing between premalignant and malignant oral conditions, unlike serum levels, highlighting its potential role in early detection.
Article Abstract
Background: Oral squamous cell carcinoma (OSCC) is thought to develop from precancerous dysplastic lesions through multistep processes of carcinogenesis involving activation of oncogenes and loss of tumor suppressor genes. The human epidermal growth factor receptor 2 (Her-2/neu [erbB-2]), a cell membrane glycoprotein, is a growth factor receptor that has receptor tyrosine kinase activity. Her2/neu activation plays a central role in cell proliferation and survival. It has been shown that overexpression of Her2/neu increases the rate of cell division and growth, leading to precancerous changes. The aim of the present study was to compare the serum and salivary Her2/neu levels between cases with premalignant and malignant oral lesions.
Materials And Methods: Fasting blood samples and unstimulated saliva by passive drooling were collected from three groups of healthy control (n=20), premalignant disorder (PMD) (n=20) and OSCC (n=25) subjects. The HER2 extracellular domain (HER2 ECD) levels were measured using ELISA.
Results: The levels of serum Her2/neu showed no significant differences between any of the groups but on the other hand salivary Her2/neu levels were found to be significantly (p<0.05) higher when compared between control (median 68.7 pg/ml, range: 21.5 - 75.8) and OSCC (median 145.6 pg/ml, range: 45.1-191.1). A similar trend was observed when comparing between PMD (median 43.3, range: 22.1 -94.7) and OSCC with a statistical significance of p<0.05.
Conclusions: Our study provided evidence of increased salivary Her2/neu in OSCC when compared to PMD and control which was not the case for serum levels. This suggests that probably Her2/neu is not highly amplified as in breast cancer so as to be reflected in serum. Since saliva is in local vicinity of the OSCC, even a mild increase might be mirrored. On the whole, this study proposes Her2/neu as marker for distinguishing premalignant and malignant conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7314/apjcp.2015.16.14.5773 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort.
Mol Diagn Ther
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University, Kirrbergerstr. 100, Building 6, 66421, Homburg, Saar, Germany.
Article Synopsis
- Salivary gland carcinomas (SGC) are diverse with 24 subtypes, primarily treated through surgery and radiotherapy, but have a low 5-year survival rate of 20% for patients with recurrence or metastasis.
- A study involving 55 SGC patients investigated various druggable molecular alterations using immunohistochemical staining and fluorescence in situ hybridization, finding a 54.4% prevalence of such alterations, with EGFR overexpression being the most common.
- Targeted therapies like trastuzumab deruxtecan and pembrolizumab may offer new treatment options for patients with RM-SGC who cannot undergo salvage surgery.
Salivary duct carcinoma in the submandibular gland: A rare case report with differential diagnosis.
J Oral Maxillofac Pathol
July 2024
Department of Oral and Maxillofacial Pathology, Sree Mookambika Institute of Dental Sciences, Kanyakumari District, Tamil Nadu, India.
Salivary duct carcinoma (SDC) is a rare and highly aggressive malignant salivary gland neoplasm, accounting for only 0.2% of salivary gland tumours. It predominantly affects the parotid gland and represents a significant concern with limited prevalence (1-1.
View Article and Find Full Text PDFCapecitabine is effective as palliative chemotherapy in a patient with androgen receptor and HER2 positive metastatic salivary duct carcinoma. A case report.
J Cancer Res Ther
October 2023
Division of Medical Oncology, Institute of Oncology Ljubljana, Zaloska ulica 2, 1000 Ljubljana, Slovenia.
Metastatic salivary duct carcinomas (SDC) are rare tumors and evidence-based guidelines for their treatment have not yet been established. Reports of such cases like ours could be beneficial in the decision-making in the similar clinical circumstances. Here we present the 64-year-old Caucasian man with bone pain and pancytopenia two years after local treatment of SDC, in whom a bone marrow biopsy revealed poorly differentiated carcinoma of salivary origin with nuclear androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2/neu) positivity.
View Article and Find Full Text PDFMetastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report.
Case Rep Oncol
November 2023
BrustZentrum Zürichsee, Horgen, Switzerland.
Introduction: Salivary duct carcinoma (SDC) is an aggressive and rare subtype of salivary gland carcinoma. Surgical excision and radiotherapy are standard of care for early cancer. Chemotherapies with taxanes and platinum show overall response rates between 39% and 50%.
View Article and Find Full Text PDFPapillary cystadenoma of the major salivary gland: A case report and review of literature.
Pathol Res Pract
November 2023
Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurugram, India. Electronic address:
Papillary cystadenoma (PC) of the salivary gland is an uncommon benign epithelial neoplasm that shows predominantly multicystic growth pattern with intraluminal papillary proliferation and areas of oncocytic differentiation. We report a case of papillary cystadenoma of the parotid gland in a 44-years-old female. The patient presented with painful nodular swelling in the right parotid region for two months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!